ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:

Dictionar de medicamente online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Dictionar medical online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Puteti trimite articole cu tema medicala la
adresa de email

Solutie antistress!
Construieste poduri :)
Joc, Construieste podul, Cargo Bridge

Prinde pisica neagra :)
Prinde pisica neagra- Chat Noir - Flash game

New Study Published In The Lancet Neurology Shows Topamax(R) Provides Sustained Reduction In Monthly Migraine Days For Up To One Year

A new long-term study into migraine prevention published in The Lancet Neurology shows that patients who continued with Topamax(R) (topiramate) for migraine prophylaxis for up to a year experienced a sustained reduction in the number of migraine days per month, with significant associated benefits on quality of life measures.1 The study also found that there was a significant increase in the number of monthly migraine days following discontinuation of topiramate, however, the number did not return to pre-treatment levels.1

Migraine is a very common disorder affecting around 11% of the adult population in the Western world.2 One UK study estimated that 5.85 million people in the UK, aged 16-65 years, experience 190,000 migraine attacks everyday resulting in the loss of 25 million days from work or school each year.3

The PROMPT (PROlonged Migraine Prevention with Topiramate) study was a 12-month, multicentre, double-blind, randomised, placebo-controlled study conducted to investigate the continued effectiveness of topiramate in reducing the number of migraine days beyond six months, compared with the impact of stopping treatment at six months. All patients received open-label Topamax for the first 6 months, and then were randomised to either continue Topamax or take placebo for the second 6 months in a double-blind design.

After 6 months of open-label topiramate treatment, the mean number of monthly migraine days fell significantly from 8.93 to 5.83, a reduction of 3.1 migraine days per month (p





Nou studiu publicat în The Lancet Neurologie Afiºeazã Topamax (R) prevede susþinut Reducerea lunar Migrene zile, pentru pânã la un an - New Study Published In The Lancet Neurology Shows Topamax(R) Provides Sustained Reduction In Monthly Migraine Days For Up To One Year - articole medicale engleza - startsanatate